在瘤学临床试验中的B7同类4 (B7-H4) 导向剂:一篇评论
Meave Phipps1, Gerald S Falchook1
1Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
Journal of immunotherapy and precision oncology
|April 11, 2025
概括
包括抗体-药物联体在内的B7-H4向疗法,在治疗三阴性乳腺癌等固体瘤方面表现有前途. 目前正在探索组合策略,以改善治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- B7同源4 (B7-H4) 是一种在各种固体瘤中过度表达的跨膜蛋白.
- 它的过度表达使B7-H4成为新型癌症治疗的重要目标.
研究的目的:
- 审查目前B7-H4向剂的情况.
- 讨论他们的临床试验进展和潜在的组合策略.
主要方法:
- 对针对B7-H4的药物的临床前和临床数据的审查.
- 对抗体-药物合物 (ADC) 和组合疗法的分析.
主要成果:
- 针对B7-H4的ADCs (puxitatug samrotecan,felmetatug vedotin,GSK5733584) 在三阴性乳腺癌中显示出早期的临床活性.
- 与抗PD-1或PARP抑制剂的联合策略在临床前模型中显示了瘤回归的增强.
结论:
- 针对B7-H4的药物,特别是ADCs,对于表达B7-H4的癌症来说是一个有前途的治疗途径.
- 组合方法有可能改善正在进行的临床试验中的患者结果.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K


